Juvenile Idiopathic Arthritis
Sandoz Enters US Immunology Market with Launch of High-Concentration Formulation Hyrimoz
SG Tylor
Source – Novartis On July 1, 2023, Sandoz made an announcement regarding the availability of their biosimilar Hyrimoz (adalimumab-adaz) injection ...
